Example 9 7-Cyclopentyl-N, N-bis(methyl-d3)-2-((5-(pipera/in- 1 -yl-2,2,3,3,5,5,6,6-dg)pyridin-2- yl)amino)-7H-pynOlo[2,3-d]pyrimidine-6-carboxamide According to the procedures described for Example S, Example 9 was prepared from 2-amino-7-cyclopentyl-N, N-bis(methyl-d3)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (commercially available, 100 mg, 0.36 mmol), and /erf-butyl 4-(6-bromopyridin-3- yl)pipera/ine-l-carboxylale-2,2,3,3,5,5,6,6-d8 (comercially available, 160 mg, 0.46 mmol) under the conditions simialr to Steps 3 and 4 in Example 2
To stablizie DHA and its conjugates it is important to add anti-oxidants to the material after it is synthesized
Directed evolution aid the following DNA vaccination goals DNA vaccination can be used for diverse goals that can include the following, among others: stimulation of a CTL response and/or humoral response ready to react rapidly and aggressively against an invading bacterial or viral pathogen at some time in the distant future a multicomponent format allows the generation of a portfolio of DNA vaccine vectors, some of which will be reconstructed on each occasion (e.g., those vectors containing antigen) while others will be used as well characterized and understood reagents for numerous different clinical applications (e.g., the same chemokine-expressing vector can be used in different situations)
These concerns are valid
References 1 ElahiS
